Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Amit Sanyal, MD: A Clinician’s Perspective

Mar

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Amit Sanyal, MD: A Clinician’s Perspective

Can Viral Respiratory Infections Increase Lung Cancer Risk

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

Early Study Evaluates Two-Vaccine Strategy in T-Cell Lymphoma

Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy

Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants